ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2015
Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Comparison of left ventricle mechanical dyssynchrony parameters in ischemic and non-ischemic patients usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Prognostic value of absent left ventricular ejection fraction reserve with regadenoson SPECT MPI.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The prognostic implications of ST-segment and T-wave abnormalities in patients undergoing regadenoson stress SPECT myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The prognostic value of regadenoson SPECT myocardial perfusion imaging: The largest cohort to date.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Regadenoson SPECT MPI post-troponin elevation in two different patient populations: A reliable risk-stratification tool.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Risk stratification with vasodilator stress SPECT myocardial perfusion imaging in patients with elevated cardiac biomarkers.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Gender-related differences in side-effects and hemodynamic response to regadenoson in patients undergoing SPECT myocardial perfusion imaging.European journal of nuclear medicine and molecular imaging · 2019Article
- Adverse effects associated with regadenoson myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Review
- The blood pressure response to vasodilator stress does not provide independent prognostic information.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Safety of stress testing in patients with elevated cardiac biomarkers: Are all modalities created equal?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Vasodilator stress agents for myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- The role of pharmacological stress testing in women.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Review
- Prognostic value of transient ischemic dilation with regadenoson myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- Review of Cardiovascular Imaging in the Journal of Nuclear Cardiology in 2015-Part 2 of 2: Myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- Heart rate response to regadenoson: Making the case for its value in clinical practice.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- The prognostic value of regadenoson stress: Has the case been made?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegadenoson is now widely used in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). However, the prognostic value of abnormal stress perfusion findings with regadenoson vs adenosine are unclear. The aim of this study was to evaluate the prognostic value of regadenoson SPECT and to compare it to that of adenosine SPECT. METHODS AND
results3698 consecutive patients undergoing either adenosine or regadenoson SPECT were assessed at 1 year for the endpoints of cardiovascular death and a composite endpoint of cardiovascular death or MI. Weighted Cox proportional hazards regression modeling with the inverse probability weighted (IPW) estimators method adjusting to propensity for agent was used to account for differences in baseline characteristics. Patients undergoing adenosine SPECT MPI had a significantly higher prevalence of smoking history, diabetes, hypertension, and prior myocardial infarction (P < .05, all). At 1 year of follow-up, there were 154 cardiovascular deaths and 204 with the composite endpoint of cardiovascular death or MI. Using IPW adjustment to propensity for agent in a model with stress agent, summed stress score (SSS) remained a significant predictor of the composite endpoint of cardiovascular death or MI (HR 1.36 CI 1.28-1.46; P < .0001) as well as cardiovascular death (HR 1.38 CI 1.28-1.49; P < .0001). The interaction of SSS with agent was not significant. Similar findings were seen with summed difference score (SDS).
conclusionsSSS derived from either adenosine or regadenoson SPECT MPI is a significant predictor of events and provides incremental prognostic information beyond basic clinical variables. We have shown for the first time that use of regadenoson vs adenosine as stress agent does not modify the prognostic significance of SSS. Similar findings were seen with SDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.